ProCE Banner Activity

ARCTIC REWIND: Tapering and Withdrawing TNF Inhibitor Associated With Higher Flare Risk in Patients With RA in Stable Remission

Slideset Download
Conference Coverage
Flares more frequent with tapered vs continued TNF inhibitor during first 12 months (63% vs 5%, respectively).

Released: November 13, 2020

Expiration: November 12, 2021

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie Inc.

Gilead Sciences, Inc.

Sanofi Genzyme Corp